- Extensive apoptosis of malignant cells
- Decreased tumor invasiveness and metastasis
- Decreased tumor and endothelial cell proliferation
- Blockade of metastatic bone lesion progression
- Disruption of tumor vasculature
Preliminary results from Exelixis' (EXEL) CaboNivo drug trial indicated issues among nine of 24 patients participating in the study.
Focus on finding stocks of high-quality companies at good prices, Cramer advises.